Neurocrine Biosciences, Inc.NBIXNASDAQ
LOADING
|||
Switch Symbol:
Net Income Growth Under Pressure
Trending lower, above historical average, modest growth trend.
Left:
||||
Year-over-year net income growth rate
Latest
94.88%
↑ 66% above average
Average (39q)
57.27%
Historical baseline
Range
High:1260.76%
Low:-706.59%
CAGR
+4.9%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 94.88% |
| Q2 2025 | 1260.76% |
| Q1 2025 | -92.34% |
| Q4 2024 | -20.57% |
| Q3 2024 | 99.69% |
| Q2 2024 | 49.77% |
| Q1 2024 | -70.62% |
| Q4 2023 | 77.74% |
| Q3 2023 | -12.98% |
| Q2 2023 | 224.67% |
| Q1 2023 | -186.07% |
| Q4 2022 | 29.93% |
| Q3 2022 | 505.33% |
| Q2 2022 | -221.58% |
| Q1 2022 | 290.41% |
| Q4 2021 | -132.44% |
| Q3 2021 | -46.81% |
| Q2 2021 | 31.78% |
| Q1 2021 | -90.77% |
| Q4 2020 | 703.99% |
| Q3 2020 | -172.36% |
| Q2 2020 | 112.83% |
| Q1 2020 | 10.00% |
| Q4 2019 | -36.79% |
| Q3 2019 | 4.77% |
| Q2 2019 | 150.27% |
| Q1 2019 | -664.86% |
| Q4 2018 | -64.39% |
| Q3 2018 | 958.52% |
| Q2 2018 | 85.86% |
| Q1 2018 | -706.59% |
| Q4 2017 | 161.97% |
| Q3 2017 | 81.45% |
| Q2 2017 | 23.42% |
| Q1 2017 | -75.39% |
| Q4 2016 | -21.07% |
| Q3 2016 | 8.42% |
| Q2 2016 | -109.09% |
| Q1 2016 | 34.29% |
| Q4 2015 | 14.87% |